CK-4021586 not checked

Cytokinetics

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
None yet
 
Trials
1 active
2 in total
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
Tested for
Symptomatic Heart Failure With Preserved Ejection Fraction (HFpEF)
Main trialPhase 2
“This is a Phase 2 dose-finding study in adult participants with symptomatic HFpEF.”In the company’s words, NCT06793371 on ClinicalTrials.gov
Other names
ulacamten

Other drugs for Symptomatic Heart Failure With Preserved Ejection Fraction (HFpEF)

All 42 drugs for Symptomatic Heart Failure With Preserved Ejection Fraction (HFpEF)

Coming up0

No dates coming up.

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials2

TrialPhaseCompletesWhat it tests
Phase 2Recruiting Sep 2026 AMBER-HFpEF: Assessment of CK-4021586 in a Multi-Center, Blinded Evaluation of Safety and Tolerability Results in HFpEF
Phase 1Completed 20 Nov 2024 A Single and Multiple Ascending Dose Study of CK-4021586 in Healthy Adult Participants
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow CK-4021586

Following is part of Solo: you see every change to CK-4021586 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in